Phase II - IV Clinical

Sophisticated Biomarkers, Including Gene Expression Profiling from Nasal Brushings, Sputum and Blood, Are Used in COPD Therapy Trial - November, 2013

This month we will begin a study of a new intervention targeting a major inflammatory mechanism in patients with chronic obstructive pulmonary disease (COPD). To this end, our respiratory team led by Dr Tjeert Mensinga (Principle Investigator) and Daniel Prins, MSc (Project Manager) will join forces with our collaborating network of pulmonologists. The study will include several sophisticated biomarkers, including gene expression profiling from nasal brushings, sputum and blood. In addition, our team is preparing for allergen challenge studies early next year.

Illustration from:

Inhaled Allergen Bronchoprovocation Tests.
Zuzana Diamant, Gail M Gauvreau, Don W Cockcroft, Louis-Philippe Boulet, Peter J Sterk, Frans H de Jongh, Barbro Dahlén, Paul M O'Byrne
The Journal of Allergy and Clinical Immunology (2013)

20 years in pharma R&D navigation